Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bastholt

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 4, 2023
Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapiesAimilia Schina, Sidsel Pedersen, Anne-Louise Spenning, et al.
Pigment Cell & Melanoma Research|March 22, 2021
Genetic predisposition to long telomeres is associated with increased mortality after melanoma: A study of 2101 melanoma patients from hospital clinics and the general populationHafsa Ismail, Jens Helby, Lisbet R Hölmich, et al.
The Journal of Investigative Dermatology|September 30, 2011
CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysisMaren Weischer, Ida M Heerfordt, Stig E Bojesen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2016
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016Claus Garbe, Ketty Peris, Axel Hauschild, et al.
The Lancet. Oncology|August 18, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialSophie Leboulleux, Lars Bastholt, Thomas Krause, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2024
Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcomeRebecca Schou Jurlander, Louise Mahncke Guldbrandt, Rikke B Holmstroem, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2019
Measured and genetically predicted plasma YKL-40 levels and melanoma mortalityHafsa Ismail, Jens Helby, Lisbet R Hölmich, et al.
American Journal of Therapeutics|June 11, 2014
Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countriesAlberto Wainstein, Salvador Martin Algarra, Lars Bastholt, et al.
Melanoma Research|May 12, 2018
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel studyPaolo A Ascierto, Lars Bastholt, Pier F Ferrucci, et al.
Journal of the National Cancer Institute|October 19, 2025
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysisYago Garitaonaindia, Shawez Khan, Rasmus Friis, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|November 4, 2023
Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapiesAimilia Schina, Sidsel Pedersen, Anne-Louise Spenning, et al.
Pigment Cell & Melanoma Research|March 22, 2021
Genetic predisposition to long telomeres is associated with increased mortality after melanoma: A study of 2101 melanoma patients from hospital clinics and the general populationHafsa Ismail, Jens Helby, Lisbet R Hölmich, et al.
The Journal of Investigative Dermatology|September 30, 2011
CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysisMaren Weischer, Ida M Heerfordt, Stig E Bojesen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2016
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016Claus Garbe, Ketty Peris, Axel Hauschild, et al.
The Lancet. Oncology|August 18, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialSophie Leboulleux, Lars Bastholt, Thomas Krause, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2024
Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcomeRebecca Schou Jurlander, Louise Mahncke Guldbrandt, Rikke B Holmstroem, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2019
Measured and genetically predicted plasma YKL-40 levels and melanoma mortalityHafsa Ismail, Jens Helby, Lisbet R Hölmich, et al.
American Journal of Therapeutics|June 11, 2014
Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countriesAlberto Wainstein, Salvador Martin Algarra, Lars Bastholt, et al.
Melanoma Research|May 12, 2018
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel studyPaolo A Ascierto, Lars Bastholt, Pier F Ferrucci, et al.
Journal of the National Cancer Institute|October 19, 2025
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysisYago Garitaonaindia, Shawez Khan, Rasmus Friis, et al.
Pageof 14